毓金方对中晚期非小细胞肺癌患者的中位无进展生存期、CA724影响的研究

发布时间：2018-03-16 02:24

本文选题：非小细胞肺癌　切入点：毓金方　出处：《黑龙江中医药大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的通过观察毓金方对中晚期非小细胞肺癌痰湿蕴肺型患者的中位无进展生存期、肿瘤标志物CEA、CA125、CA724水平的影响,以探讨毓金方对中晚期非小细胞肺癌痰湿蕴肺型患者的治疗效果。方法将2015年9月至2016年4月在黑龙江中医药大学附属第一医院肿瘤科病房治疗并符合纳入标准的中晚期非小细胞肺癌痰湿蕴肺型的患者60例,随机分为两组,每组30例。所有患者均被病理确诊。试验组口服毓金方联合静脉滴注康莱特注射液,具体用药方法为毓金方每日1剂,水煎汁300ml,分作2袋,患者分别于早餐前、晚睡前2小时温服,1袋/次,2次/日,连服3周,休息1周,静脉滴注康莱特注射液200ml/次,1次/日,连续静脉滴注3周,休息1周,毓金方与康莱特用药均以28天为1周期,连续治疗6周期;对照组静脉滴注康莱特注射液,具体用法用量及疗程同试验组。每3个月进行复查和随访,观察和比较两组患者中位无进展生存期的长短和肿瘤标志物的变化。结果1.研究显示,试验组的中位无进展时间为5.80个月;对照组的中位无进展时间为4.50个月,P0.05,差异具有统计学意义。2.试验组及对照组血清肿瘤标志物CEA、CA125、CA724水平均呈现逐渐下降趋势,在治疗后第3个月、6个月、9个月治疗组CEA、CA724水平比对照组下降程度明显,差异具有统计学意义(P0.05)。3.治疗3个月后,试验组的血清CA125水平比对照组下降程度未见明显差异,P0.05,不具有统计学意义。4.在治疗后第6个月、9个月试验组血清CA125水平比对照组下降程度有明显差异,具有统计学意义(P0.05)。5.试验组中医证候积分在在治疗后3个月与对照组差异不具有统计学意义(P0.05),在治疗后6个月、9个月,试验组与对照组中医证候积分差异具有统计学意义(P0.05)。结论1.毓金方能延长中晚期非小细胞肺癌(痰湿蕴肺型)患者的中位无进展生存期;2.毓金方能明显降低中晚期非小细胞肺癌(痰湿蕴肺型)患者血清肿瘤标志物CEA、CA125、CA724表达水平;3.毓金方能够有效改善中晚期非小细胞肺癌(痰湿蕴肺型)患者的临床症状,降低中医证候积分。
[Abstract]:Objective to observe the effect of Yujin recipe on the median progressive survival time and the level of tumor marker CEA CA125 and CA724 in patients with middle and late stage non-small cell lung cancer with phlegm-dampness accumulation. To explore the therapeutic effect of Yujin recipe on the patients with lung type of phlegm dampness accumulation in middle and advanced non-small cell lung cancer. Methods from September 2015 to April 2016, the treatment was carried out in the oncology ward of the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine and was in accordance with the standard of inclusion. A total of 60 patients with advanced non-small cell lung cancer with phlegm dampness and lung type, The patients were divided into two groups randomly, 30 cases in each group. All the patients were confirmed by pathology. In the experimental group, Yujin prescription was given orally and Kanglaite injection was given intravenously. The specific methods were Yujin prescription once a day, decoction juice 300ml, divided into 2 bags, the patients were divided into two bags before breakfast. Two hours before bedtime, warm clothes (1 bag / second time / day), continuous administration for 3 weeks, rest for 1 week, intravenous drip of Kanglaite injection 200ml / times per day, continuous intravenous drip for 3 weeks, rest for 1 week. Both Yujin Fang and Kanglaite were given 28 days as one cycle. The control group received intravenous drip of Kanglaite injection, the dosage and course of treatment were the same as the experimental group. The median progression-free survival time and the changes of tumor markers were observed and compared between the two groups. Results 1.The study showed that the median progression-free time was 5.80 months in the trial group. The median time of no progression in the control group was 4.50 months (P 0.05), the difference was statistically significant. 2. The level of serum tumor marker CEACA125 CA724 in the experimental group and control group showed a decreasing trend. After 3 months, 6 months and 9 months of treatment, the level of CEA CA724 in the treatment group was significantly lower than that in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the level of serum CA125 between the test group and the control group (P 0.05). There was no significant difference in the level of serum CA125 between the test group and the control group at the 6th month and the 9th month after treatment, and there was a significant difference in the level of serum CA125 between the test group and the control group. The scores of TCM syndromes in the test group were not significantly different from those in the control group in 3 months after treatment, but in 6 months and 9 months after treatment. The difference of TCM syndromes integral between the test group and the control group is statistically significant (P 0.05). Conclusion 1.Yujin prescription can prolong the median progression-free survival time of patients with intermediate and advanced non-small cell lung cancer (phlegm-dampness accumulation lung type) 2.Yujin prescription can obviously reduce the middle and late stage of lung cancer. The expression level of serum tumor marker CEACA125 and CA724 in patients with stage non-small cell lung cancer (phlegm-dampness accumulation lung type). Yujin prescription can effectively improve the clinical symptoms of patients with intermediate and advanced non-small cell lung cancer (phlegm-dampness accumulation lung type). Reduce the integral of TCM syndromes.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R273

【参考文献】